Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press3110.17650/1994-4098-2014-0-2-68-72GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕClinical case use bevacizumab for patient with metastatic ovarian cancerКлинический случай применения бевацизумаба у пациентки с метастатическим раком яичникаOganyanM. R.ОганянМ. Р.
Russian Federation
kapurol@mail.ruDavidenkoO. V.ДавиденкоО. В.
Russian Federation
Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, KrasnodarГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар17072014268721807201418072014https://ojrs.abvpress.ru/ojrs/article/view/31

High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the improving of the results of survival, further study of the use of bevacizumab in metastatic ovarian cancer therapy is necessary.М.Р. Оганян, О.В. ДавиденкоГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар Контакты: Мариэтта Рафаэловна Оганян kapurol@mail.ru

Высокая заболеваемость и смертность больных раком яичника (РЯ), короткий безрецидивный период, проводимые неоднократные последующие операции и курсы химиотерапии, а также невысокие показатели выживаемости обусловливают актуальность проблемы лечения данной патологии. В настоящее время наиболее эффективными режимом химиотерапии 1-й и 2-й линий III и IV стадий РЯ является комбинация платины с паклитакселом (гемцитабином) в сочетании с таргетным препаратом (бе- вацизумабом). Учитывая высокую эффективность данной комбинации, в целях улучшения результатов выживаемости необхо- димо дальнейшее изучение бевацизумаба в терапии метастатического РЯ в практике лечебных учреждений.

metastatic ovarian cancerangiogenesisbevacizumabметастатический рак яичниковангиогенезбевацизумаб1. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71–96.Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71–96.2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer 2013.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer 2013.3. du Bois A., Quinn M., Thigpen T. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8:viii7–12.du Bois A., Quinn M., Thigpen T. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8:viii7–12.4. Ozols R.F., Bundy B.N., Greer B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194– 200.Ozols R.F., Bundy B.N., Greer B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194– 200.5. du Bois A., Lück H.J., Meier W. et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first- line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320–9.du Bois A., Lück H.J., Meier W. et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first- line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320–9.6. Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002;3(9):529–36.Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002;3(9):529–36.7. Piccart M.J., Bertelsen K., James K. et al. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699–708.Piccart M.J., Bertelsen K., James K. et al. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699–708.8. Ledermann J.A., Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006;5:341–54.Ledermann J.A., Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006;5:341–54.9. Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21(10 Suppl):149s–67s.Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21(10 Suppl):149s–67s.10. Sullivan D.С., Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003;89(2):228–31.Sullivan D.С., Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003;89(2):228–31.11. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5(4):194–204.Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5(4):194–204.12. Hartenbach E.M., Olson T.A., Goswitz J.J. et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121(2):169–75.Hartenbach E.M., Olson T.A., Goswitz J.J. et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121(2):169–75.13. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121(1):230–8.Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121(1):230–8.14. Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100(1):1–7.Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100(1):1–7.15. Teoh D.G., Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011;18(1):31–43.Teoh D.G., Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011;18(1):31–43.16. Kabbinavar F.F., Wong J.T., Ayala R.E. et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995;36:488.Kabbinavar F.F., Wong J.T., Ayala R.E. et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995;36:488.17. Perren T., Swartz A.M,. Pfisterer J. et al. ICON7: A phase III randomised Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010;21(Suppl 8): аbstr LBA4.Perren T., Swartz A.M,. Pfisterer J. et al. ICON7: A phase III randomised Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010;21(Suppl 8): аbstr LBA4.18. Burger R.A., Brady M.F., Bookman M.A. et al. Phase III trial of bevacizumab (BEV)Burger R.A., Brady M.F., Bookman M.A. et al. Phase III trial of bevacizumab (BEV)in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010;28(suppl):аbstr LBA1.19. Burger R.A., Brady M.F., Rhee J. et al. Independent radiologic review of the Gynecologic Oncology Group study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Gynecol Oncol 2013;131(1): 21–6.Burger R.A., Brady M.F., Rhee J. et al. Independent radiologic review of the Gynecologic Oncology Group study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Gynecol Oncol 2013;131(1): 21–6.20. Penson R.T., Dizon D.S., Cannistra S.A. et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010;28:154–9.Penson R.T., Dizon D.S., Cannistra S.A. et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010;28:154–9.21. Burger R.A., Sill M.W., Monk B.J. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: а Gynecologic Oncology Group study. J Clin Oncol 2007;25(33):5165–71.Burger R.A., Sill M.W., Monk B.J. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: а Gynecologic Oncology Group study. J Clin Oncol 2007;25(33):5165–71.22. Garcia A.A., Hirte H., Fleming G. et al. Phase II clinical trial of bevacizumab and low- dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess MargaretGarcia A.A., Hirte H., Fleming G. et al. Phase II clinical trial of bevacizumab and low- dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess MargaretHospital рhase II сonsortia. J Clin Oncol 2008;26(1):76–82.23. McGonigle K.F., Muntz H.G., Vuky J. et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum- resistant ovarian, primary peritoneal, or fallopian tube cancer (OV). J Clin Oncol 2008;26 (15 Suppl):abstr 5551.McGonigle K.F., Muntz H.G., Vuky J. et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum- resistant ovarian, primary peritoneal, or fallopian tube cancer (OV). J Clin Oncol 2008;26 (15 Suppl):abstr 5551.24. Aghajanian C., Blank S.V., Goff B.A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039–45.Aghajanian C., Blank S.V., Goff B.A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039–45.